Literature DB >> 9084957

Target concentration strategy for cyclosporin monitoring.

R G Morris1.   

Abstract

The target concentration concept has been proposed as a potential alternative to the established, and probably much abused, therapeutic range method of interpreting concentrations of therapeutic drugs in plasma, serum or blood when individualising drug dosages. This paper raises for debate the possibility of extending this alternative concept to immunosuppressant monitoring with cyclosporin, where there has been considerable difficulty in establishing therapeutic ranges which are widely accepted and applied. In its broader application, the target concentration strategy does present advantage to the clinician in precision, ability to calculate the dose directly from the target concentration and clearance, as well as a clearer concept of an optimal concentration (differentiating desired and adverse effects).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084957     DOI: 10.2165/00003088-199732030-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

Review 2.  Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel.

Authors:  L M Shaw; R W Yatscoff; L D Bowers; D J Freeman; J R Jeffery; P A Keown; I J McGilveray; T G Rosano; P Y Wong
Journal:  Clin Chem       Date:  1990-10       Impact factor: 8.327

Review 3.  Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

Authors:  B D Kahan; L M Shaw; D Holt; J Grevel; A Johnston
Journal:  Clin Chem       Date:  1990-08       Impact factor: 8.327

Review 4.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

5.  Survey of cyclosporine therapeutic ranges, assay methodology, and use of 'sparing agents' in Australasian transplant centers.

Authors:  T E Jones; R G Morris
Journal:  Ther Drug Monit       Date:  1997-12       Impact factor: 3.681

Review 6.  Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel.

Authors:  M Oellerich; V W Armstrong; B Kahan; L Shaw; D W Holt; R Yatscoff; A Lindholm; P Halloran; K Gallicano; K Wonigeit
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

Review 7.  Methodological and clinical aspects of cyclosporin monitoring: report of the Association of Clinical Biochemists task force.

Authors:  D W Holt; A Johnston; N B Roberts; J M Tredger; A K Trull
Journal:  Ann Clin Biochem       Date:  1994-09       Impact factor: 2.057

8.  Cyclosporin A monitoring in Australia: consensus recommendations.

Authors:  R G Morris; S E Tett; J E Ray
Journal:  Ther Drug Monit       Date:  1994-12       Impact factor: 3.681

9.  Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial.

Authors:  N Holford; P Black; R Couch; J Kennedy; R Briant
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

10.  Specific enzyme-multiplied immunoassay and fluorescence polarization immunoassay for cyclosporin compared with Cyclotrac [125I]radioimmunoassay.

Authors:  R G Morris; N C Saccoia; R G Ryall; M K Peacock; B C Sallustio
Journal:  Ther Drug Monit       Date:  1992-06       Impact factor: 3.681

View more
  7 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

3.  Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

Authors:  Hélène Bourgoin; Gilles Paintaud; Matthias Büchler; Yvon Lebranchu; Elisabeth Autret-Leca; France Mentré; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 4.  Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations.

Authors:  María del Mar Fernández De Gatta; Dolores Santos-Buelga; Alfonso Domínguez-Gil; María José García
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

Authors:  M H Ensom; G A Davis; C D Cropp; R J Ensom
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

Review 6.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 7.  Optimizing Mycophenolic Acid Exposure in Kidney Transplant Recipients: Time for Target Concentration Intervention.

Authors:  David K Metz; Nick Holford; Joshua Y Kausman; Amanda Walker; Noel Cranswick; Christine E Staatz; Katherine A Barraclough; Francesco Ierino
Journal:  Transplantation       Date:  2019-10       Impact factor: 4.939

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.